Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Formycon AG operates within the Biotechnology & Pharmaceuticals technology area, maintaining a portfolio that currently features 3 pending office actions. These actions are distributed across 3 distinct examiners and 3 distinct art units, indicating a broad spread of technical review within the patent office. The busiest examiner, BUTTICE, AUDREY L, is responsible for 1 pending action, which is a portion of the total 3 pending office actions currently active for the company.
The distribution of 3 pending office actions among 3 distinct examiners suggests that Formycon AG is engaging with multiple different perspectives and examination styles. This variety is mirrored in the 3 distinct art units, showing that the company's Biotechnology & Pharmaceuticals applications are being evaluated across several specialized divisions. The fact that the busiest examiner, BUTTICE, AUDREY L, only has 1 pending action highlights the lack of concentration in the current prosecution pipeline.
With 3 pending office actions and 3 distinct examiners, the portfolio demonstrates a high level of examiner diversity. Each of the 3 distinct art units likely brings its own set of standards and timelines to the cases. This structure means that the company's overall progress is not overly dependent on any single examiner, as BUTTICE, AUDREY L only manages 1 of the active cases.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUTTICE, AUDREY L | 1 | 46.6% | +26.0% |
| SANG, HONG | 1 | 54.9% | +62.8% |
| MOSS, NATALIE M | 1 | 30.7% | +17.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18573798 | FORMULATIONS OF ANTI-PD1 ANTIBODIES | BUTTICE, AUDREY L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786423 | FORMULATIONS OF ANTI-PD1 ANTIBODIES | SANG, HONG | 9d |
| 18573798 | FORMULATIONS OF ANTI-PD1 ANTIBODIES | BUTTICE, AUDREY L | — |
| 17610894 | METHOD FOR REDUCING METHIONINE OXIDATION IN RECOMBINANT PROTEINS | MOSS, NATALIE M | — |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| 1646 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18573798 | FORMULATIONS OF ANTI-PD1 ANTIBODIES | BUTTICE, AUDREY L | 1647 | §102§103 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 17786423 | FORMULATIONS OF ANTI-PD1 ANTIBODIES | SANG, HONG | 1646 | DP | Final Rejection | 9d | Pending | Jun 16, 2022 |
| 17610894 | METHOD FOR REDUCING METHIONINE OXIDATION IN RECOMBINANT PROTEINS | MOSS, NATALIE M | 1653 | §103 | Non-Final OA | — | Pending | Nov 12, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFormycon AG has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Audrey L Buttice has the most, with 1 of Formycon AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
